Time and spatial trends in lymphoid leukemia and lymphoma incidence and survival among children and adolescents in Manitoba, Canada: 1984-2013

Xibiao Ye¹,²*, Mahmoud Torabi¹, Lisa M. Lix¹,², Salaheddin M. Mahmud¹,²

¹ Department of Community Health Sciences, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada, ² George & Fay Yee Centre for Healthcare Innovation, University of Manitoba, Winnipeg, Manitoba, Canada

* xibiao.ye@gmail.com

Abstract

Objectives

To test for time and spatial trends in lymphoid malignancies, including lymphoid leukemia (LL), Hodgkin lymphoma (HL), and non-Hodgkin lymphoma (NHL), in children and adolescents in the province of Manitoba, Canada.

Methods

Incident cases diagnosed between 1984 and 2013 were identified from the Manitoba Cancer Registry. We assessed time trends in age-standardized incidence rates using joinpoint regression and in 5-year relative survival using Poisson regression model. Kulldorff’s scan method was used to assess spatial variation and clustering.

Results

Age-standardized incidence rates (per million person-years) in males and females were 34.0 (95% confidence interval [CI] 28.9–39.1) and 26.2 (95% CI 21.5–30.7) for LL, 10.5 (95% CI 7.7–13.3) and 12.5 (95% CI 9.4–15.7) for HL, 12.5 (95% CI 9.3–15.4) and 7.7 (95% CI 5.2–10.2) for NHL (except for Burkitt lymphomas), and 3.2 (95% CI 1.6–4.7) and 1.5 (95% CI 0.4–2.5) for Burkitt lymphomas. Age- and sex- standardized LL incidence rate increased 1.4% (95% CI 0.3%-2.5%) per year, while the changes for HL and NHL incidence rates were not statistically significant. There were geographic differences in age-standardized incidence rates for LL, HL, and NHL and spatial clusters were detected in southern part of the province. Five-year relative survival has improved over time and there was no difference between rural and urban areas.

Conclusions

Lymphoid leukemia incidence rate increased over time and varied by geographic area. Further research should examine the factors contributing to these trends.
Introduction

Hematological malignancies as a group are the most common cancer in children (under age of 15 years) and adolescents (15–19 years) and account for 40% of total cancer cases in this population [1]. Acute lymphoid leukemia (ALL) is the most common hematological malignancy, followed by Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) [1]. Little is known about the etiology of the cancers and there are only a few established risk factors, including high-level ionizing radiation [2], certain chemotherapeutic agents [3] (e.g., diethylstilbestrol [4]), certain genetic disorders (e.g., Down syndrome [5]), and congenital immunodeficiency diseases [1].

Analyzing time and spatial trends of cancer incidence may provide useful information to generate new hypotheses for etiological research. Despite extensive research on time trends in hematological malignancy incidence in adults, few studies have been conducted in children and adolescents. A recent international comparative analysis showed differences in temporal trends in leukemia and lymphoma incidence rates in children by country [6]. Data have also shown geographical variations in incidence among children and adolescents at the country level [7–11], but less is known about the variation within smaller areas (e.g., provinces or regions). Short-term and long-term survival of hematological malignancy patients have been improved over time [1,7,10], but disparities related to factors such as ethnicity and geography have been shown [12–14]. In this article, we present data on incidence and survival and their time and spatial trends for lymphoid malignancies in children (under 15 years) and adolescents (15 to 19 years) in the province of Manitoba, Canada.

Materials and methods

Data sources

Cancer diagnosis information was retrieved from the Manitoba Cancer Registry (MCR), a population-based registry operated by CancerCare Manitoba (CCMB). Cancer patients were originally coded using different editions of the International Classification of Disease for Oncology (ICD-O) and were converted to the 3rd edition (ICD-O-3) [15]. Reporting of cancer cases to the MCR is mandatory and MCR is regularly audited by the North American Association of Central Cancer Registries [16]. The quality of cancer registry data has been consistently very high. Most cases are pathologically-confirmed (94% for cases registered between 2006 and 2010) and less than 2% of registrations originate from death certificates [16].

Histology and topography codes were used to identify lymphoid leukemia (ICD-O-3 histology codes 9835–9836), Hodgkin lymphoma (ICD-O-3 histology codes 9650–9655, 9659, 9661–9665, 9667), and non-Hodgkin lymphoma (ICD-O-3 histology codes 9590–9591, 9596, 9670–9671, 9673, 9675, 9678–9680, 9684, 9687, 9688–9691, 9695, 9698–9702, 9705, 9708–9709, 9714, 9716–9719, 9724–9729, 9731–9735, 9737–9738, 9760–9762, 9764–9769, 9970; 9811–9818, 9837, 9823, and 9827 when C000-C419, C422-C423, C425-C809 as ICD-O-3 site). Cases were then classified using the International Classification of Childhood Cancer, 3rd Edition (ICCC-3) [17].

Other patient characteristics including sex, age at diagnosis, year of diagnosis, residential location at the time of diagnosis (i.e., 6-digit postal code) were also obtained from the MCR. All child and adolescent cases registered with MCR between 1984 and 2013 were included. Household income quintile at diagnosis was determined based on dissemination area level average household income derived from Canadian Census data [18]. Manitoba population counts by age, sex, and year were obtained from the Manitoba Health Insurance Registry. This research was approved by the University of Manitoba Research Ethics Board, Manitoba.
Health Information Privacy Committee, and CancerCare Manitoba Research Resource Impact Committee.

Statistical analysis

The total number of incident cases were described by sex and subtype. Sex ratios and median age of diagnosis were also calculated. Age was grouped using 5-year intervals (0–4, 5–9, 10–14, 15–19 years). Annual age-standardized incidence rates were calculated using the 2006 Canadian population as the standard population. Age-specific incidence rates were also calculated. We tested the time trend in incidence using the Joinpoint Regression Program [19]. The joinpoint regression method first tested the trend with no joinpoint (i.e., linear model) and then determined whether more joinpoints (up to 3) need to be added, based on Permutation Test and Bayesian Information Criterion [20]. Annual percentage change (APC) and 95% confidence intervals (CIs) were estimated [20].

In Manitoba, regional health authorities (RHAs, 5 in total as of 2013) are responsible for the delivery and administration of health services in a specific geographical area. Each RHA is divided into smaller geographical regions. These include 25 neighborhood clusters in the provincial capital Winnipeg, with an average of 6,500 children and adolescents in each cluster as of July 1, 2013. As well, there are 72 districts, with an average of 2,300 children and adolescents in each district, outside of Winnipeg. For the spatial analysis, we first assigned each case to a single district or neighborhood cluster according to the 6-digit postal code for the patient’s place of residence at the date of diagnosis. We used an empirical Bayes method to estimate smoothed incidence rate ratios by geographical area, adjusting for sex, age, and average household income at diagnosis (area-based income measurement) [21]. Ratios for districts were calculated using the incidence for the entire province as the reference; ratios for Winnipeg neighborhood clusters were calculated using Winnipeg incidence rate as the reference. Kullendorf’s scan method was used for cluster detection [22,23]. The most likely cluster, i.e., the cluster that is least likely to be due to chance is identified. All spatial analyses were conducted using R package “SpatialEpi (version 1.2.1)” [24].

We calculated 5-year relative survival, the ratio of observed survival of cancer patients to the expected survival of a comparable Canadian general population assumed free of cancer, using the period analysis method [25]. Expected survival was calculated based on Canadian age- and sex- specific mortality by year provided by the Human Mortality Database (www.mortality.org/), according to the Ederer II method [26]. Standard errors for relative survival were calculated using the Greenwood method and 95% confidence intervals were derived using logarithmic transformation [27]. A Poisson regression model was used to test the time trend in 5-year relative survival, using the R package periodR (version 1.0.6) [28,29]. We used multivariable Cox proportional hazards regression models to test the association between patient survival and residential area (urban [Winnipeg and Brandon] vs. rural), controlling for age at diagnosis, sex, year of diagnosis, and income quintile [30]. The proportional hazards (PH) assumption was examined using graphical and statistical approaches [30]. An interaction term with survival time was added to the model when a variable violated the PH assumption. Cox proportional hazards regression was undertaken using SAS 9.3 (SAS Institute, Cary, North Carolina).

Results

Between 1984 and 2013, 511 cases (including 296 LL, 113 HL, and 100 NHL cases) were diagnosed in children and adolescents (Table 1). HL accounted for 45.6% of lymphomas in males and 60.6% in females. The sex ratios (M/F) were 1.4 for LL, 0.9 for HL, 1.7 for NHL (except
Burkitt lymphomas (BL), and 2.3 for BL. The median age at diagnosis ranged from 4 years (for LL) to 17 years (for mature B-cell lymphoma except BL).

Table 2 shows the age-standardized incidence rate (per million person-years) by sex and type. Age-standardized LL incidence rates were 34.0 (95% CI 28.9–39.1) and 26.2 (95% CI 21.5–30.7) in males and females, respectively. HL incidence rates were similar for males (10.5, 95% CI 7.7–13.3) and females (12.5, 95% CI 9.4–15.7). However, males had the higher

---

**Table 1. Lymphoid leukemia and lymphoma cases diagnosed among children and adolescents in Manitoba: 1984–2013.**

| Classification | Overall | Male | Female | M/F Ratio | Median age (years) at diagnosis |
|----------------|---------|------|--------|-----------|--------------------------------|
| Total          | 511     | 287  | 224    |           |                                |
| Lymphoid leukemia | 296     | 171  | 125    | 1.4       | 4                              |
| Hodgkin lymphoma          | 113     | 53   | 60     | 0.9       | 17                             |
| Non-Hodgkin lymphoma (overall) | 100     | 63   | 37     | 1.7       | 12                             |
| Non-Hodgkin lymphoma (except Burkitt lymphomas) | 77     | 47   | 30     | 1.6       | 14                             |
| Precursor cell lymphomas | 23      | 14   | 9      | 1.6       | 12                             |
| Mature B-cell lymphomas (except Burkitt lymphomas) | 30     | 17   | 13     | 1.3       | 17                             |
| Mature T-cell and NK-cell lymphomas | 13 | 8 | S | 1.6 | 13 |
| Non-Hodgkin lymphomas, NOS | 11 | 8 | S | 2.7 | 12 |
| Burkitt lymphoma/leukemia | 23 | 16 | 7 | 2.3 | 9 |
| Unspecified lymphomas | S | 0 | S | 8.5 | |

NOS, not otherwise specified; S, suppressed for any values under 6.

---

**Table 2. Age-standardized lymphoid leukemia and lymphoma incidence rates (per million person-years) in children and adolescents in Manitoba, Canada: 1984–2013.**

| Classification | Male | Female |
|----------------|------|--------|
|                | 0–14 years | 0–19 years | 0–14 years | 0–19 years |
|                | N | Rate (95% CI) | N | Rate (95% CI) | N | Rate (95% CI) | N | Rate (95% CI) |
| Lymphoid leukemia | 155 | 41.5 (34.9–48.0) | 171 | 34.0 (28.9–39.1) | 117 | 32.9 (25.9–38.9) | 125 | 26.2 (21.5–30.7) |
| Hodgkin lymphoma | 19 | 5.1 (2.8–7.4) | 53 | 10.5 (7.7–13.3) | 13 | 3.7 (1.7–5.6) | 60 | 12.5 (9.4–15.7) |
| Non-Hodgkin lymphoma (overall) | 40 | 10.7 (7.4–14.0) | 63 | 12.5 (9.3–15.4) | 23 | 6.5 (3.8–9.1) | 37 | 7.7 (5.2–10.2) |
| Non-Hodgkin lymphoma (except Burkitt lymphomas) | 27 | 7.2 (4.5–9.9) | 47 | 9.3 (6.7–12.0) | 17 | 4.8 (2.5–7.1) | 30 | 6.3 (4.0–8.5) |
| Precursor cell lymphomas | 11 | 2.9 (1.2–4.7) | 14 | 2.8 (1.3–4.2) | S | 1.4 (0.2–2.6) | 9 | 1.9 (0.6–3.1) |
| Mature B-cell lymphomas (except Burkitt lymphomas) | 6 | 1.6 (0.3–2.9) | 17 | 3.4 (1.8–4.9) | S | 1.4 (0.2–2.6) | 13 | 2.7 (1.2–4.2) |
| Mature T-cell and NK-cell lymphomas | 6 | 1.6 (0.3–2.9) | 8 | 1.6 (0.5–2.7) | S | 1.4 (0.2–2.6) | S | 1.0 (0.1–1.9) |
| Non-Hodgkin lymphomas, NOS | S | 1.1 (0.0–2.1) | 8 | 1.6 (0.5–2.7) | S | 0.6 (0.0–1.3) | S | 0.6 (0.0–1.3) |
| Burkitt lymphoma/leukemia | 13 | 3.5 (1.9–5.4) | 16 | 3.2 (1.6–4.7) | 6 | 0.7 (0.3–3.0) | 7 | 1.5 (0.4–2.5) |
| Unspecified lymphomas | 0 | | | | | | S | 0.6 (0.0–1.3) |

N; number of case; NOS, not otherwise specified; S, suppressed for any values under 6.

---

https://doi.org/10.1371/journal.pone.0175701.t001

https://doi.org/10.1371/journal.pone.0175701.t002
incidence rates for overall NHL (12.5 vs 7.7), NHL except Burkitt lymphomas (9.3 vs. 6.3), and precursor cell lymphomas (2.8 vs 1.9) than females.

In the joinpoint analyses, zero joinpoint (i.e., straight line) was the best model to represent the time trends in LL, HL, and NHL incidence. While age- and sex-standardized LL incidence rates increased (APC = 1.4%, 95% CI 0.3% ~ 2.5%) over the past 3 decades (1984–2013), the rates for HL (APC = 0.2%, 95% CI -1.6% ~ 2.0%) and NHL (APC = -1.9%, 95% CI -5.9% ~ 2.3%) were relatively stable (Fig 1).

Spatial analysis showed geographical variations in incidence rates of all types across the province and within Winnipeg. Outside Winnipeg, incidence rates for LL, HL, and NHL in Southern districts tended to be high, compared to the provincial average (Fig 2). Most likely clusters were identified in southern districts for all three types (S1 Fig). High incidence for NHL was observed in three northern districts, but no clustering was detected in this area. In Winnipeg, most likely clusters were found in Northwestern neighborhood clusters for LL, HL, and NHL (S1 Fig).

Ten-year and 15-year relative survival was slightly lower than 5-year relative survival for all types (S1 Table). Females generally had better survival than males. There was an trend of improved 5-year relative survival for all types of cancers, and the improvement was statistically significant for NHL in both males and females (Table 3). The greatest increase was observed for NHL in females, from 58.5% in 1984–1993 to 90.7% in 2004–2013. In the most recent period (2004–2013), 5-year relative survival was greater than 85% for all three types of cancers. In the Cox proportional hazards regression model, no statistically significant difference in patient survival was found between rural and urban areas, but the survival has improved over-time (S2 Table).

Discussion

In this analysis, we estimated age-specific and standardised incidence rates for lymphoid malignancies in children and adolescents in Manitoba, Canada. Age-specific incidence patterns for LL, HL, and NHL are similar to that reported across the world [6]. The etiology of childhood hematological malignancies is poorly understood and there are only a few established risk factors [31]. The peak incidence rate for LL at age 0–4 years is consistent with the in utero origin hypothesis for childhood leukemia [32].

Age-standardized incidence rates for LL, HL, and NHL in Manitoba children and adolescents are in the range of those reported in Canada [33–37], United States [1], and other countries [8,38,39]. Countries around the world have different time trends in LL and lymphoma incidence rates [9]. We did not find published information on the time trend in LL incidence in Canadian children and adolescents. The present analysis showed that LL incidence rates in Manitoban children and adolescents increased 1.4% per year during 1984–2013. Overall leukemia incidence rates in Canadian boys increased by 0.8% annually during 1992–2010 [33], and this is largely driven by the increase (2.4% per year) during 1992–1999 [34]. Temporal trends in LL incidence varied by country: LL incidence rates increased 0.7% per year in children and adolescents in the United States (1975–2010) [1], 0.6% per year in children and 1.9% per year in adolescents in Europe (1978–1997) [40], but the increases in Western Australia (1960–2006) [41] and in Shanghai, China (1973–2005) [42] were not statistically significant. Rising incidence could be attributed to increased exposure to risk factors (e.g., environmental exposures) and/or diagnostic improvement. Further research is warranted to explore changes in risk factors for childhood LL [31] in the province and their possible contributions to the rise in incidence.
Fig 1. Time trends for age- and sex-standardized lymphoid leukemia (a), Hodgkin lymphoma (b), and non-Hodgkin lymphoma (c) incidence in children and adolescents in Manitoba, Canada: 1984–2013.

https://doi.org/10.1371/journal.pone.0175701.g001
Fig 2. Geographical variations in lymphoid leukemia (LL), Hodgkin lymphoma (HL), and non-Hodgkin lymphoma (NHL) incidence in children and adolescents in Manitoba, Canada: 1984–2013.

https://doi.org/10.1371/journal.pone.0175701.g002
While HL incidence rates decreased 0.7% annually in children in USA (1975–2010) [1], the rates increased 1% per year among children aged 10–14 years and 3.5% per year among adolescents in Europe during 1978–1997 [43]. Like in this analysis, a previous study found no increase in incidence rate for NHL in children of Canada [35]. But NHL incidence rates increased 0.9% per year in children and 1.7% per year in adolescents during 1978–1997 in Europe [44] and increased 1.1% per year during 1975–2010 in USA [1]. Rising HL incidence when NHL incidence is declining have been attributed to diagnostic misclassification of NHL as HL [45]. When HL and NHL were combined, incidence rates were stable in Canada (1992–2010) [33], Australia (1983–2006) [46], and China (1973–2005) [42]. Age-standardized incidence rates for BL (one of the most common NHL subtypes) in males and females, were higher than that reported in a recent analysis of BL cases registered with the International Agency for Research on Cancer [47]. The risk of endemic BL in Africa is related to malaria, Epstein-Barr virus, and human immunodeficiency virus infections, but little is known about the etiology of sporadic BL [48]. Further research is needed to explain the high BL incidence in this province.

The observed spatial variations in LL, HL, and NHL incidence in this study and others [7,49,50] indicate variations in exposure to genetic and environmental risk factors. Genetic factors account for a small proportion of childhood cancers and environmental factors may play a greater role [51]. Point source of known carcinogens such as radiation was associated with increased leukemia risk in children living nearby [52]. The higher incidence in southern Manitoba, where socioeconomic status (SES) is better than that in other areas, is consistent with the finding from some of previous studies in other jurisdictions. Communities with high area-based measure of SES had higher childhood leukemia incidence than those with lower SES [53–55], but the association was not observed in other ecological studies [56,57]. On the contrary, many studies with individual-level SES measures found an inverse association between SES and childhood leukemia incidence [58,59]. Overall, findings regarding the association between SES and childhood leukemia risk are mixed. The heterogeneity may be due to differences in place and calendar time when the studies were undertaken and in SES measures used [58,59]. Fewer studies have examined the association between SES and lymphoma (HL and NHL) incidence [56,60]. Geographic variations remained after adjusting for average household income, indicating other area-related factors (e.g., environmental exposures) might play a role. However, without data on the geographical difference in risk factor exposures, it is unclear whether and to what extent the distributions of these risk factors have contributed to

| Classification     | Sex          | 1984–1993 | 1994–2003 | 2004–2013 | Difference between 2004–2013 and 1984–1993 |
|--------------------|--------------|-----------|-----------|-----------|------------------------------------------|
|                    | N            | Relative Survival | N          | Relative Survival | N                        | Relative Survival | P value for time trend test * |
| Lymphoid leukemia  | Male         | 47         | 76.5 (7.1) | 84         | 76.9 (5.7) | 94                | 87.9 (4.3) | 11.4 | 0.06 |
|                    | Female       | 44         | 87.3 (6.1) | 64         | 90.9 (4.4) | 61                | 95.3 (3.3) | 8.0  | 0.17 |
|                    | Overall      | 91         | 81.4 (4.8) | 144        | 83.1 (3.8) | 155               | 90.9 (2.9) | 9.5  | 0.03 |
| Hodgkin lymphoma   | Male         | 21         | 88.4 (11.1)| 33         | 83.1 (7.8) | 22                | 100           | 11.6 | 0.08 |
|                    | Female       | 16         | 100        | 27         | 94.8 (5.4) | 35                | 100           | 0    | 0.13 |
|                    | Overall      | 37         | 94.2 (5.9) | 60         | 88.3 (5.0) | 57                | 100           | 5.8  | 0.02 |
| Non-Hodgkin lymphoma | Male    | 27         | 74.4 (9.3) | 26         | 86.7 (8.8) | 28                | 85.9 (7.6) | 11.5 | 0.04 |
|                    | Female       | 14         | 58.5 (14.5)| 16         | 64.4 (12.8) | 14                | 90.7 (9.1) | 32.2 | 0.03 |
|                    | Overall      | 41         | 69.7 (7.8) | 42         | 75.1 (8.2) | 42                | 87.4 (5.9) | 17.7 | 0.003 |

Note: numbers in parentheses are standard errors. NOS, not otherwise specified. N, number of case.
* p value for time trend from Poisson regression model.

https://doi.org/10.1371/journal.pone.0175701.t003
the geographical disparities. The interpretation of the higher NHL incidence in remote Northern regions may require caution due to the very small population size in these areas. It is unlikely that environmental exposures played a role, but infections and diet might.

Similar to those reported in other jurisdictions [1,8,38,39], the vast majority of children and adolescents have survived for longer than 5 years after leukemia/lymphoma diagnosis. Survival of patients with LL, HL, and NHL has increased over time in Manitoba and other areas [1,8,38,39], most likely reflecting the treatment improvement for leukemia and lymphoma patients. As treatment advances, the number of child and adolescent leukemia and lymphoma survivors will continue to increase. Appropriate therapy-related and risk-based long-term follow-up is important to monitor late effects (e.g., pulmonary dysfunction, cardiac disease, infertility, and second malignant neoplasms) of treatments and to improve those patients’ quality of life [61].

Previous studies have shown geographical disparities in childhood leukemia and lymphoma survival related to remoteness and SES [7,13,62,63]. But no statistically significant difference in survivals was found between patients living in rural and urban areas in the present study, which may reflect improved access due to the implementation in 1978 of the Manitoba Community Cancer Programs Network (MCCPN) program, a provincial program operated by CancerCare Manitoba (CCMB) to provide rural cancer patients care and treatment in or near their own communities [64]. The MCCPN program has 16 outpatient units located in community hospitals across the province, avoiding nine million kilometers of travel to and from urban centers for patients and their families each year [65].

This study has some limitations. Reporting delay [66], the time elapsed before a diagnosed cancer case is reported to a cancer registry, was not used to adjust incidence rate calculations as delay adjustment data are not available for this population. The delay primarily affects the estimation of incidence rates in the most recent 1 to 3 years (2011–2013 in this case) and the actual incidence rates in these years might have been underestimated. Spatial analysis was based on the most recent geographical boundary, but postal code and boundary went through several changes during the study period. In the Cox regression model, we combined the three cancer types in order to generate more robust analysis (higher number of cases). However, the three types of lymphoid cancers are heterogeneous. The prognosis of lymphoid malignancy patients is determined by many factors other than those tested in the analysis. LL patients are at different levels of risk associated with phenotype, age at diagnosis, initial white blood cell count, and other prognostic factors, but we did not have sufficient data and sample size for subgroup analysis. The mortality rate was not reported because of the extremely low number of death cases in children and adolescents in the province (28 LL deaths, 1 HL death, and 25 NHL deaths during 1982–2014). Other studies demonstrated that LL, HL, and NHL were cancer types with the most significant mortality declines in children and adolescents over the past three decades [1,67].

The analysis showed an increase in LL incidence but not in the other two types in the province of Manitoba, Canada. Geographical variation and clustering in leukemia and lymphoma incidence might be due to differences in risk factors, but further research is needed to identify possible factors and their relations to leukemia and lymphoma risk. The observed survival improvement likely reflects advances in leukemia and lymphoma treatments for children and adolescents.

**Supporting information**

S1 Fig. Most likely clusters for lymphoid leukemia (LL), Hodgkin lymphoma (HL), and non-Hodgkin lymphoma (NHL) incidence in children and adolescents in Manitoba,
Canada: 1984–2013.

S1 Table. Observed and relative survival by sex in children and adolescents with lymphoid leukemia or lymphoma in Manitoba, Canada, 1984–2013.

S2 Table. Hazard ratios (HRs) and 95% confidence intervals (CIs) from Cox regression model.

Acknowledgments

The authors acknowledge the Manitoba Centre for Health Policy for use of data contained in the Population Health Research Data Repository under project 2015–028 (HIPC 2015/2016-04). The results and conclusions are those of the authors and no official endorsement by the Manitoba Centre for Health Policy, Manitoba Health, Healthy Living, and Seniors, or other data providers is intended or should be inferred.

Author Contributions

Conceptualization: XY.

Data curation: XY.

Formal analysis: XY MT.

Funding acquisition: XY.

Investigation: XY LML SMM MT.

Methodology: XY SMM MT.

Project administration: XY.

Resources: XY.

Software: XY.

Supervision: XY.

Validation: XY.

Visualization: XY.

Writing – original draft: XY.

Writing – review & editing: SMM LML MT.

References

1. Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin [Internet]. 2014; 64(2):83–103. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24488779 https://doi.org/10.3322/caac.21219 PMID: 24488779

2. Harvey EB, Boice JD, Honeyman M, Flannery JT. Prenatal x-ray exposure and childhood cancer in twins. N Engl J Med [Internet]. 1985 Feb 28 [cited 2015 Sep 17]; 312(9):541–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3969117 https://doi.org/10.1056/NEJM198502283120903 PMID: 3969117
Katz AJ, Chia VM, Schoonen WM, Kelsh MA. Acute lymphoblastic leukemia: an assessment of international incidence and survival among children and adolescents ages 0–19 years. Int J Cancer. 2015; 1874:1862–74.

3. Stolley PD, Zahm SH. Nonhormonal drugs and cancer. Environ Health Perspect [Internet]. 1995 Nov [cited 2015 Sep 17]; 103 Suppl:191–6. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?articld=1518949&tool=pmcentrez&rendertype=abstract

4. Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med [Internet]. 1971 Apr 15 [cited 2015 Aug 4]; 284(15):878–81. Available from: http://www.ncbi.nlm.nih.gov/pubmed/5549830 https://doi.org/10.1056/NEJM197104152841506 PMID: 5549830

5. Xavier AC, Taub JW. Acute leukemia in children with Down syndrome. Haematologica [Internet]. 2010 Jul 1 [cited 2016 Feb 18]; 95(7):1043–5. Available from: http://www.haematologica.org/content/95/7/1043 https://doi.org/10.3324/haematol.2010.024968 PMID: 20595099

6. Linet MS, Brown LM, Mbuliayte SM, Check D, Ostroumova E, Landgren A, et al. International long-term trends and recent patterns in the incidence of leukemias and lymphomas among children and adolescents ages 0–19 years. Int J Cancer. 2015; 1874:1862–74.

7. Steliarova-Foucher E, Stiller C, Kaatsch P, Berrino F, Coebergh J-W, Lacour B, et al. Geographical patterns and time trends of cancer incidence and survival among children and adolescents in Europe since the 1970s (the ACCISproject): an epidemiological study. Lancet (London, England) [Internet]. 2004 Jan [cited 2016 Mar 9]; 364(9451):2097–105. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-1034424481&partnerID=Z0tx3y1

8. Izarzugaza MI, Steliarova-Foucher E, Martos MC, Zivkovic S. Non-Hodgkin’s lymphoma incidence and survival in European children and adolescents (1978–1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer [Internet]. 2006 Sep [cited 2015 Nov 21]; 42(13):2550–63. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-33747354085&partnerID=Z0tx3y1 https://doi.org/10.1016/j.ejca.2006.05.005 PMID: 16919770

9. Linet MS, Brown LM, Mbuliayte SM, Check D, Ostroumova E, Landgren A, et al. International long-term trends and recent patterns in the incidence of leukemias and lymphomas among children and adolescents ages 0–19 years. Int J Cancer. 2015;

10. Katz AJ, Chia VM, Schoonen WM, Kelsh MA. Acute lymphoblastic leukemia: an assessment of international incidence, survival, and disease burden. Cancer Causes Control [Internet]. Springer International Publishing; 2015; 26(11):1627–42. Available from: http://link.springer.com/10.1007/s10552-015-0657-6 PMID: 26376890

11. Parkin DM, Kramerová E, Draper GJ, Masuyer E. International Incidence of Childhood Cancer, Vol. II. IARC Sci Publ [Internet]. 1998 Jan [cited 2016 Mar 17];(144):1–391. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10370892 PMID: 10370892

12. Walters S, Quaresma M, Coleman MP, Gordon E, Forman D, Rachet B. Geographical variation in cancer survival in England, 1991–2006: an analysis by Cancer Network. J Epidemiol Community Heal. 2011; 65(11):1044–52.

13. Njoku K, Basta N, Mann KD, McNally RJQ, Pearce MS. Socioeconomic variation in survival from childhood leukemia in northern England, 1968–2010. Br J Cancer [Internet]. 2013 Jun 11 [cited 2016 Apr 11]; 108(11):2339–45. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?articld=3681006&tool=pmcentrez&rendertype=abstract https://doi.org/10.1038/bjc.2013.222 PMID: 23652301

14. Kent EE, Breen N, Lewis DR, de Moor JS, Smith AW, Seibel NL. US trends in survival disparities among adolescents and young adults with non-Hodgkin lymphoma. Cancer Causes Control [Internet]. Kluwer Academic Publishers; 2015 Aug [cited 2016 May 11]; 26(8):1153–62. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-84937642721&partnerID=Z0tx3y1 https://doi.org/10.1007/s10552-015-0609-1 PMID: 26084209

15. Organization WH. International classification of diseases for oncology, 3rd edition. 2000.

16. Copeland G, Lake A, Firth R, Wohler B, Wu XC, Stroup A, et al. Cancer in North America: 2006–2010. Volume One: Combined Cancer Incidence for the United States, Canada and North America. 2013.

17. Steliarova-Foucher E, Stiller C, Lacour B, Kaatsch P. International classification of childhood cancer, third edition. Cancer. 2005; 103(7):1457–67. https://doi.org/10.1002/cncr.20910 PMID: 15712273

18. Brownell M, Martens P, Kozyrskyj A, Fergusson P, Lerfald J, Mayer T, et al. Assessing the Health of Children in Manitoba: A Population-Based Study. 2001.

19. Joinpoint Regression Program, Version 4.3.1.0—April 2016; Statistical Methodology and Applications Branch, Surveillance Research Program, National Cancer Institute.

20. Kim HJ, Fay MP, Feuer EJ M D. Permutation tests for jointpoint regression with applications to cancer rates. Stat Med. 2000; 19(April 1998):335–51.

21. Clayton D, Kaldor J. Empirical Bayes estimates of age-standardized relative risks for use in disease mapping. Biometrics [Internet]. 1987 Sep [cited 2016 Mar 15]; 43(3):671–81. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3663823 PMID: 3663823
22. Zhang Z, Assunção R, Kulldorff M. Spatial scan statistics adjusted for multiple clusters. J Probab Stat. 2010; 2010.

23. Kulldorff M. A spatial scan statistic. Commun Stat—Theory Methods [Internet]. Marcel Dekker, Inc.; 1997 Jun 27 [cited 2016 Feb 1]; 26:1484–96. Available from: http://www.tandfonline.com/doi/abs/10.1080/03610929708831995

24. Chen AC, Kim AY, Ross M, Wakefield J, Kim MAY. Package “SpatialEpi.” 2015;

25. Brenner H, Gefeller O, Hakulinen T. Period analysis for “up-to-date” cancer survival data: Theory, empirical evaluation, computational realisation and applications. Eur J Cancer. 2004; 40(3):326–35. PMID: 14746849

26. Ederer F, Heise H. Instructions to IBM 650 Programmers in Processing Survival Computations. Methodological note no. 10. Bathesda, MD: 1959.

27. Swaminathan R, Brenner H. Statistical methods for cancer survival analysis. IARC Sci Publ [Internet]. Division of Epidemiology and Cancer Registry, Cancer Institute (W.I.A), Chennai, Tamil Nadu, India.; 2011;(162):7–13. Available from: https://www.scopus.com/inward/record.url?eid=2-s2.0-79959804512&partnerID=40&md5=ca4939ebbb2b96881f5b923f4b847e PMID: 21675401

28. Holleck B, Gondos A, Brenner H. Period R—An R package to calculate long-term cancer survival estimates using period analysis. Methods Inf Med [Internet]. Saarland Cancer Registry, Präsident-Baltz-Strasse 5, 66119 Saarbrücken, Germany; 2009; 48(2):123–8. Available from: https://www.scopus.com/inward/record.url?eid=2-s2.0-68549090805&partnerID=40&md5=b78458d14eab9d65769c4f187c4983ea https://doi.org/10.3414/ME0563 PMID: 19283308

29. Holleck B, Brenner H. Model based period analysis of absolute and relative survival with R. Data preparation, model fitting and derivation of survival estimates. Comput Methods Programs Biomed [Internet]. Elsevier Ireland Ltd; 2013; 110(2):192–202. Available from: http://dx.doi.org/10.1016/j.cmpb.2012.10.004 PMID: 23116992

30. Cox DR, Oakes D. editors. Analysis of survival data. New York: Chapman and Hall; 1984.

31. Spector LG, Street D, Pankratz N, Marcotte EL. Genetic and nongenetic risk factors for childhood cancer. Pediatr Clin North Am [Internet]. Elsevier Inc; 2015; 62(1):11–25. Available from: http://dx.doi.org/10.1016/pocl.2014.09.013 PMID: 25435109

32. Greaves M. Pre-natal Origins of Childhood Leukemia [Internet]. Reviews in Clinical and Experimental Hematology. 2003. p. 233–45. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-0345763041&partnerID=tZOtx3y1 PMID: 15024967

33. Ellison L, Jantz T. Health at a Glance Childhood cancer incidence and mortality in Canada. 2015;(82).

34. Mitra D, Shaw AK, Hutchings K. Trends in incidence of childhood cancer in Canada, 1992–2006 [Internet]. Chronic Diseases and Injuries in Canada. 2012. p. 131–9. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-84863441447&partnerID=tZOtx3y1 PMID: 22762899

35. Liu S, Semenciw R, Mao Y, Lui S, Semenciw R, Mao Y. Increasing incidence of non-Hodgkin’s lymphoma in children and young adults from the north of England, 1990–2002. Eur J Cancer [Internet]. Elsevier Ltd; 2011 Oct 24 [cited 2015 Sep 7]; 47(12):57–66. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-0037838831&partnerID=tZOtx3y1 PMID: 12802810

36. Stammers DM, Israels SJ, Lambert PJ, Cuvelier GDE. Cancer incidence, morbidity, and survival in Canadian first nation children: a Manitoba population-based study from the cancer in young people in Canada (CYP-C) registry. Pediatr Blood Cancer. 2014; 61:2164–9. https://doi.org/10.1002/hon.2015 Sep 7]; 21(2):57–66. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-0037838831&partnerID=tZOtx3y1 PMID: 12802810

37. Kulkarni K, Stobart K, Witol A, Rosychuk RJ. Leukemia and Lymphoma Incidence in Children in Alberta, Canada: A Population-based 22-year Retrospective Study. Pediatr Hematol Oncol [Internet]. Taylor & Francis; 2011 Oct 24 [cited 2015 Sep 16]; Available from: http://www.tandfonline.com/doi/abs/10.3109/08880018.2011.613091?journalCode=pho20

38. Kaatsch P. Epidemiology of childhood cancer. Cancer Treat Rev [Internet]. Elsevier Ltd; 2010 Jun [cited 2014 Nov 20]; 36(4):277–85. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-77959804512&partnerID=40&md5=ca4939ebbb2b96881f5b923f4b847e PMID: 2031056

39. Feltbower RG, McNally PJQ, Kinsey SE, Lewis IJ, Picton S V, Proctor SJ, et al. Epidemiology of leukaemia and lymphoma in children and young adults from the north of England, 1990–2002. Eur J Cancer [Internet]. Elsevier Ltd; 2008; 45(3):420–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19004628 https://doi.org/10.1016/j.ejca.2009.02.003 PMID: 19004628

40. Coebergh JWW, Reedijk AMJ, de Vries E, Martos C, Jakab Z, Stelianova-Foucher E, et al. Leukaemia incidence and survival in children and adolescents in Europe during 1978–1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer [Internet]. 2006 Sep [cited 2016 Apr 12]; 42(13):209–36. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16919768 https://doi.org/10.1016/j.ejca.2006.06.005 PMID: 16919768
41. Milne E, Laurvick CL, de Klerk N, Robertson L, Thompson JR, Bower C. Trends in childhood acute lymphoblastic leukemia in Western Australia, 1960–2006. Int J Cancer. 2008; 122(5):1130–4. https://doi.org/10.1002/ijc.23326 PMID: 17985340

42. Bao P, Zheng Y, Gu K, Wang C, Wu C, Jin F, et al. Trends in childhood cancer incidence and mortality in urban Shanghai, 1973–2005. Pediatr Blood Cancer [Internet]. 2010 Jul 1 [cited 2016 Mar 17]; 54(7):1009–13. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-77951737836&partnerID=tZObx3y1 https://doi.org/10.1002/pbc.22383 PMID: 20052777

43. Clavel J, Steliarova-Foucher E, Berger C, Donan S, Valerianova Z. Hodgkin’s disease incidence and survival in European children and adolescents (1978–1997): report from the Automated Cancer Information System project. Eur J Cancer [Internet]. 2006 Sep [cited 2016 Apr 12]; 42(13):2037–49. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16919769 https://doi.org/10.1016/j.ejca.2006.05.012 PMID: 16919769

44. Iazarzugaza MI, Steliarova-Foucher E, Martos MC, Zivkovic S. Non-Hodgkin’s lymphoma incidence and survival in European children and adolescents (1978–1997): report from the Automated Childhood Cancer Information System project. Eur J Cancer [Internet]. 2005 Jun [cited 2016 Mar 17]; 41(8):1345–60. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15859040 https://doi.org/10.1016/j.ejca.2005.04.005 PMID: 15859040

45. Jarrett RF, Krajewski AS, Angus B, Freeland J, Taylor PR, Taylor GM, et al. The Scotland and Newcaste- lepidemiological study of Hodgkin’s disease: impact of histopathological review and EBV status on incidence estimates. J Clin Pathol [Internet]. 2003 Nov [cited 2016 Jun 22]; 56(11):811–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14600123 PMID: 14600123

46. Youliden DR, Baade PD, Valery PC, Ward LJ, Green AC, Aitken JF. Childhood cancer mortality in Australia. Cancer Epidemiol [Internet]. 2012 Oct [cited 2016 Feb 20]; 36(5):476–80. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-84865862940&partnerID=tZObx3y1 https://doi.org/10.1016/j.canep.2012.06.001 PMID: 22739323

47. Mbulaiteye SM, Anderson WF, Ferlay J, Bhatia K, Rosenberg PS, et al. Pediatric, elderly, and emerging adult-onset peaks in Burkitt’s lymphoma incidence diagnosed in four continents, excluding Africa. Am J Hematol [Internet]. 2012 Jun [cited 2016 Jun 22]; 87(6):573–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22488262 https://doi.org/10.1002/ajh.23187 PMID: 22488262

48. Mbulaiteye SM, Morton LM, Sampson JN, Chang ET, Costas L, de Sanjose S, et al. Medical history, lifestyle, family history, and occupational risk factors for sporadic Burkitt lymphoma/leukemia: the Interlymph Non-Hodgkin Lymphoma Subtypes Project. J Natl Cancer Inst Monogr [Internet]. Oxford University Press; 2014 Aug [cited 2016 Jun 22]; 2014(48):106–14. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25174031 https://doi.org/10.1093/jncimonographs/igu003 PMID: 25174031

49. Torabi M, Singh H, Galloway K, Israels SJ. Geographical variation in the incidence of childhood leukaemia in Manitoba. J Paediatr Child Health [Internet]. 2015; n/a–n/a. Available from: http://doi.wiley.com/10.1111/jpc.12930

50. Hung G-Y, Hong J-L, Yen H-J, Lee C-Y, Lee Y-S. Geographic Variation in Cancer Incidence among Children and Adolescents in Taiwan (1995–2009). PLoS One [Internet]. Public Library of Science; 2015 Jan [cited 2016 Apr 16]; 10(7):e0133051. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-84941247917&partnerID=tZObx3y1 https://doi.org/10.1371/journal.pone.0133051 PMID: 26192415

51. Spector LG, Pankratz N, Marcotte EL. Genetic and nongenetic risk factors for childhood cancer. Pediatr Clin North Am [Internet]. W.B. Saunders; 2015 Feb [cited 2015 Jul 16]; 62(1):11–25. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-84915746221&partnerID=tZObx3y1 https://doi.org/10.1016/j.pcl.2014.09.013 PMID: 25435109

52. Michelozzi P. Adult and Childhood Leukemia near a High-Power Radio Station in Rome, Italy. Am J Epidemiol [Internet]. 2002 Jun 15 [cited 2016 Apr 11]; 155(12):1096–103. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-00370975777&partnerID=tZObx3y1 PMID: 12048223

53. Kroll ME, Stiller CA, Murphy MFG, Carpenter LM. Childhood leukaemia and socioeconomic status in England and Wales 1976–2005: evidence of higher incidence in relatively affluent communities persists over time. Br J Cancer [Internet]. 2011 Nov 22 [cited 2015 Sep 17]; 105(11):1783–7. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3242592&tool=pmcentrez&rendertype=abstract https://doi.org/10.1038/bjc.2011.415 PMID: 22027710

54. Ribeiro KB, Bufler PA, Metayer C. Socioeconomic status and childhood acute lymphocytic leukemia incidence in São Paulo, Brazil. Int J Cancer [Internet]. 2008 Oct 15 [cited 2016 Apr 7]; 123(8):1907–12. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-51949105882&partnerID=tZObx3y1 https://doi.org/10.1002/ijc.23738 PMID: 18688860

55. Borugian MJ, Spinelli JJ, Mezgi G, Wilkins R, Abanto Z, McBride ML. Childhood leukemia and socioeconomic status in Canada. Epidemiology [Internet]. 2005 Jul [cited 2016 Apr 7]; 16(4):526–31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15951671 PMID: 15951671
56. Youlden DR, Baade PD, Valery PC, Hassall TE, Ward LJ, Green AC, et al. Area-based differentials in childhood cancer incidence in Australia, 1996–2006. Pediatr Blood Cancer [Internet]. 2012 Mar [cited 2016 Apr 7]; 58(3):390–4. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-84855613562&partnerID=ZObx3y1 https://doi.org/10.1002/pbc.23115 PMID: 21425449

57. Adam M, Kuehni CE, Spoerri A, Schmidlin K, Gumn-Pause F, Brazzola P, et al. Socioeconomic Status and Childhood Leukemia Incidence in Switzerland. Front Oncol [Internet]. Frontiers Research Foundation; 2015 Jan [cited 2016 Apr 7]; 5(JUN):139. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-84934268134&partnerID=ZObx3y1

58. Adam M, Rebholz CE, Egger M, Zwahlen M, Kuehni CE. Childhood leukaemia and socioeconomic status: what is the evidence? Radiat Prot Dosimetry [Internet]. 2008 Jan [cited 2016 Apr 7]; 132(2):246–54. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-58549118755&partnerID=ZObx3y1 https://doi.org/10.1093/rpd/cnc261 PMID: 18927134

59. Poole C, Greenland S, Luetters C, Kelsey JL, Mezzi G. Socioeconomic status and childhood leukaemia: A review. Int J Epidemiol. 2006; 35(2):370–84. https://doi.org/10.1093/ije/dyi248 PMID: 16308412

60. Mezzi G, Borujian MJ, Spinelli JJ, Wilkins R, Abanto Z, McBride ML. Socioeconomic status and childhood solid tumor and lymphoma incidence in Canada. Am J Epidemiol [Internet]. 2006; 164(2):170–5. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-33745620147&partnerID=40&md5=5a30e821cede5a5e81e7e4a083d85cf9 https://doi.org/10.1093/aje/kwj118 PMID: 16624952

61. Children’s Oncology Group. Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers, Version 4.0. [Internet]. 2014. http://www.survivorshipguidelines.org/

62. Youlden DR, Baade PD, Valery PC, Ward LJ, Green AC, Aitken JF. Differentials in survival for childhood cancer in Australia by remoteness of residence and area disadvantage. Cancer Epidemiol Biomarkers Prev. 2011; 20(1):1649–56. https://doi.org/10.1158/1055-9965.EPI-11-0432 PMID: 21708938

63. Schillinger JA, Grosclaude PC, Honjo S, Quinn MJ, Sloggett A, Coleman MP. Survival after acute lymphocytic leukaemia: Effects of socioeconomic status and geographic region. Arch Dis Child [Internet]. BMJ Publishing Group; 1999; 80(4):311–7. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-0032935326&partnerID=ZObx3y1 PMID: 10086933

64. CancerCare Manitoba. Community Cancer Programs Network [Internet]. http://www.cancercare.mb.ca/home/patients_and_family/treatment_services/treating_patients_in_rural_manitoba/community_cancer_programs_network/

65. CancerCare Manitoba. Manitoba’s Cancer Strategy: 2012–2017. Winnipeg, MB; 2012.

66. Clegg LX. Impact of Reporting Delay and Reporting Error on Cancer Incidence Rates and Trends. CancerSpectrum Knowl Environ [Internet]. 2002 Oct 16 [cited 2016 Feb 28]; 94(20):1537–45. Available from: http://jncc.oxfordjournals.org/content/94/20/1537.full?view=long&pmid=12381706

67. Smith MA, Altekruse SF, Adamson PC, Reaman GH, Seibel NL. Declining childhood and adolescent cancer mortality. Cancer [Internet]. John Wiley and Sons Inc.; 2014 Aug 15 [cited 2016 Mar 17]; 120(16):2497–506. Available from: http://www.scopus.com/inward/record.url?eid=2-s2.0-84905665527&partnerID=ZObx3y1 https://doi.org/10.1002/cncr.28748 PMID: 24853691